See other companies on Otta
AiCure
AI for clinical trial & patient data insights
- 101-200 employees
- Healthcare
- B2B
- Artificial Intelligence
- SaaS
- 19 West 24th Street Floor 11, New York, NY 10010, US
Jump to section
Company mission
To revolutionize healthcare by delivering patient insights to improve clinical trials.
35% employee growth in 12 months
Otta's take
Xav Kearney
CTO of Otta
AiCure leverages artificial intelligence to observe patient behaviour and gain a closer and more scalable understanding of how they respond to various treatments. This is something that the current health system struggles to manage, and results in over 15% of Medicare patients returning to hospital within 6 months of discharge, which ultimately, costs the industry around $25 billion.
AiCure places a large focus on analyzing and encouraging improved patient behaviour and commitment to medication courses. By issuing simple reminders through its patient facing app for patients to take their medication, 90% of users are adhering to their treatment. Their data ingestion and visualization platform documents real time and predictive insights into the efficacy of clinical medical trials and patient care.
The company launched in 2010 with public funding from the National Institute of Health, and has since gone on to raise over $50 million in capital investment input from Palisade Growth Capital, Singtel Innov8 and Silicon Valley Bank, showing that there’s good faith in their offering.
Benefits
- Comprehensive Healthcare Plans
- Great Location
- Stocked Pantry
- Fully Stocked Kitchen
- Catered Monthly Meals
- 401K Retirement Plans
- Team Social Events and Outings
- Learning Stipend
- Rewards for Awarded Patents
- Work from home opportunities
Company values
- Have a lasting and quantifiable impact on human health
- Think of our technology and innovation as you would a medicine
- Focus on the user
- Make it great and continuously improve
- Never assume, verify, because lives depend on it
- Be collaborative, respectful and accountable
- Be optimistic, be proactive and even if you’ve never done it before, try your best
Funding (last 2 of 8 rounds)
Jan 2024
$4m
LATE VC
Nov 2019
$24.5m
SERIES C
$69.7m
Total funding
This company has top investors
Founders
Adam Hanina
(Founder)Studied Physics & Economics at Brown, Management at Cambridge, and MBA from Pennsylvania. Managing Director of Biodeo for 4 years. European Business Development at Cerner Corporation for 3 years. Executive Director of European eHealth Forum.